Insider Selling: Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Sells 10,757 Shares of Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction on Monday, January 13th. The stock was sold at an average price of $9.10, for a total value of $97,888.70. Following the sale, the chief financial officer now owns 226,097 shares of the company’s stock, valued at approximately $2,057,482.70. This trade represents a 4.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Mineralys Therapeutics Price Performance

Shares of NASDAQ:MLYS opened at $9.83 on Thursday. The business’s 50 day moving average is $12.37 and its 200 day moving average is $12.49. Mineralys Therapeutics, Inc. has a 52-week low of $7.95 and a 52-week high of $16.91.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings results on Monday, November 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.30). During the same period last year, the company earned ($0.57) earnings per share. On average, sell-side analysts forecast that Mineralys Therapeutics, Inc. will post -3.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of Mineralys Therapeutics in a report on Tuesday, November 12th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in Mineralys Therapeutics during the third quarter valued at approximately $110,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Mineralys Therapeutics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,564 shares of the company’s stock valued at $116,000 after acquiring an additional 3,732 shares during the period. Federated Hermes Inc. raised its position in shares of Mineralys Therapeutics by 100.0% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $140,000 after acquiring an additional 6,000 shares in the last quarter. PDT Partners LLC bought a new stake in Mineralys Therapeutics during the third quarter valued at about $148,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Mineralys Therapeutics in the second quarter valued at about $145,000. 84.46% of the stock is currently owned by institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.